Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bicalutamide plus albumin-bound paclitaxel versus albumin-bound paclitaxel in AR-positive advanced triple-negative breast cancer
ChiCTR1900021220Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bicalutamide and paclitaxel in triple-negative breast cancer (TNBC) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Progression-free survival. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
bicalutamidepaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR1900021220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021220.